Blood tests to find out, in advance, if a tumor will respond to a treatment have been available for a while.  In Japan, a doctor is routinely using a blood test called RGCC to predict how his patients are going to respond to chemotherapy and other treatments.  In this test almost every patient, even though suffering from a variety of different cancers, responded positively to Onkobel®, a mix of Pao pereira and Rauwolfia vomitoria prepared according to Dr. Beljanski ‘s precise specifications.

The results have been posted on the Beljanski Foundation ‘s website.

Here is a recent article on the subject:

A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping doctors predict which patients may respond best to some immunotherapies.

Initial data on Roche’s new test aimed at determining tumor mutational burden, or TMB, was released on Friday at the European Society for Medical Oncology (ESMO) congress in Madrid. There are no TMB blood tests on the market now, Roche said.